1 BTC
=
- USD
Relay Therapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Relay Therapeutics, Inc. Common Stock
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
Market Statistics
Trading Metrics
How to Buy RLAY
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy RLAY
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesRelay Therapeutics announced promising phase 2 trial results for zovegalisib in treating vascular anomalies, with a 60% volumetric response rate. The clinical-stage biotech has a well-capitalized position with $642 million in cash, a structured path to market including a planned phase 3 trial in early 2027, and a diversified pipeline. However, as a pre-revenue company, it faces significant binary risk dependent on the clinical and regulatory success of its lead therapy.
Relay Therapeutics priced an underwritten public offering of 22.9 million shares at $12.00 per share, raising approximately $275 million in gross proceeds. The offering is expected to close on May 22, 2026. The clinical-stage biotech company is developing precision medicine therapies, with its lead asset zovegalisib currently in Phase 3 trials for HR+/HER2- metastatic breast cancer and being investigated for PIK3CA-driven vascular anomalies.
Relay Therapeutics stock surged 7.87% on Wednesday following positive Phase 2 results for zovegalisib, a vascular anomalies treatment, which showed 60% patient response rates at 12 weeks—exceeding analyst expectations. Two analysts raised their price targets (Barclays to $27, Citizens JMP to $21) and maintained buy ratings. The gains were partially offset by the company's announcement of a secondary stock offering exceeding $200 million.
Relay Therapeutics announced promising Phase 2 clinical data for zovegalisib in treating PIK3CA-driven vascular anomalies, demonstrating a 60% volumetric response rate at 12 weeks with strong safety and tolerability profiles supporting chronic dosing. The drug showed clinical improvement in 89% of patients per investigator assessment and 79% per patient assessment, with no treatment discontinuations due to adverse events. Expansion cohorts have opened at 400mg once daily and 300mg twice daily doses.
Relay Therapeutics announced positive clinical data for zovegalisib combined with Pfizer's atirmociclib and endocrine therapy in heavily pre-treated metastatic breast cancer patients, showing 44% ORR with favorable tolerability. The company plans to initiate a Phase 3 frontline trial in early 2027 with a supply agreement in place with Pfizer for atirmociclib.